| Date | Title | Description | Source |
| 12.03.2024 | Opioid Use Disorder Market to Reach USD 6.15 Billion by 2030... | Opioid Use Disorder (OUD) Market
Opioid Use Disorder Market Analysis, Industry Trends and Growth Out... | einpresswi... |
| 16.03.2017 | Glimmers of hope for science & healthcare in the punishi... | An ominous gray cloud drifted over science on Thursday, with the release of the Trump administration... | medcitynew... |
| 12.05.2015 | Pharma company’s app supports treatment for opioid abuse | It reasons that most people have a mobile phone so having an app as an access point is the easiest w... | medcitynew... |
| 27.02.2013 | 4 life sciences CEOs on lessons learned the hard way | Tim Willis, president, CEO and co-founder, TearScience: “We were out raising a series C, and we thou... | medcitynew... |
| 21.05.2012 | BDSI’s cancer pain product preps for Europe, triggers $2.5M ... | The U.S. Food and Drug Administration approved Onsolis in 2009, though the product has experienced s... | medcitynew... |
| 17.04.2012 | Patent award to BDSI triggers $15M milestone payment from En... | The USPTO had signaled earlier this year that it would issue a patent for the technology. In Februar... | medcitynew... |
| 12.03.2012 | FDA concerns delay relaunch of BDSI cancer pain product Onso... | “They’re strictly related to the appearance of the product,” BDSI vice president of marketing Al Med... | medcitynew... |
| 16.02.2012 | BDSI to get patent; issuance triggers $15M milestone from pa... | The milestone payment will be coming from drug partner Endo Pharmaceuticals (NASDAQ:ENDP). Raleigh, ... | medcitynew... |
| 06.02.2012 | $40M stock offering filed by BioDelivery Sciences Internatio... | The Endo deal, which gave BDSI $30 million up front, secures a partner responsible for the phase 3 t... | medcitynew... |
| 06.01.2012 | Chronic pain treatment from BDSI licensed to Endo Pharma in ... | “Endo is committed to serving as an integrated solutions provider for the development and commercial... | medcitynew... |
| 30.12.2011 | How FDA changes to ‘REMS’ rules helps BioDelivery Sciences... | Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration pl... | medcitynew... |
| 15.11.2011 | BDSI needs partner to finance round 2 of phase 3 trials in c... | BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as... | medcitynew... |
| 29.09.2011 | BDSI: Pharma partners still interested in pain drug’s $500M ... | “When you look across the pain category, this represents one of the few opportunities of this magnit... | medcitynew... |
| 28.09.2011 | BDSI pain drug fails in phase 3 trials but company plans new... | Investors saw otherwise and BDSI’s stock price plunged more than 39 percent to $1.85 in after hours ... | medcitynew... |
| 06.09.2011 | BDSI’s opioid-addiction drug candidate aims to challenge mar... | “If the results from this pivotal study are positive, we could be in a position to submit a New Drug... | medcitynew... |
| 22.08.2011 | BDSI’s cancer pain treatment Onsolis now slated for 3Q Canad... | But problems at the site of the contract manufacturer have delayed Onsolis’ Canada launch three time... | medcitynew... |
| 08.06.2011 | FDA’s REMS program puts BDSI at a disadvantage in cancer dru... | BDSI has been working with the FDA on changes to get its lead product on the same footing as its com... | medcitynew... |
| 21.03.2011 | NC pharma BioDelivery Sciences gets patent extension in Cana... | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems stri... | medcitynew... |
| - | BDSI needs partner to finance round 2 of phase 3 trials in c... | BioDelivery Sciences International (NASDAQ:BDSI) is running low on cash and running short on time as... | medcitynew... |
| - | $40M stock offering filed by BioDelivery Sciences Internatio... | A month after licensing a clinical-stage chronic pain treatment to Endo Pharmaceuticals (NASDAQ:ENDP... | medcitynew... |
| - | How FDA changes to ‘REMS’ rules helps BioDelivery Sciences... | Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration pl... | medcitynew... |
| - | 4 life sciences CEOs on lessons learned the hard way | There are some lessons that no amount of reading can teach an entrepreneur. Sometimes, you just have... | medcitynew... |
| - | Chronic pain treatment from BDSI licensed to Endo Pharma in ... | The investigational chronic pain treatment from BioDelivery Sciences International (NASDAQ:BDSI) tha... | medcitynew... |
| - | BDSI’s cancer pain treatment Onsolis now slated for 3Q Canad... | BioDelivery Sciences International‘s (NASDAQ:BDSI) treatment for breakthrough cancer pain is now sla... | medcitynew... |
| - | Pharma company’s app supports treatment for opioid abuse | Many of the apps that pharma companies are developing to support conditions or specific drugs and di... | medcitynew... |
| - | NC pharma BioDelivery Sciences gets patent extension in Cana... | North Carolina pharmaceutical company BioDelivery Sciences International has extended its patent in ... | medcitynew... |
| - | Glimmers of hope for science & healthcare in the punishi... | An ominous gray cloud drifted over science on Thursday, with the release of the Trump administration... | medcitynew... |
| - | BDSI’s opioid-addiction drug candidate aims to challenge mar... | An opioid-dependence treatment being developed by BioDelivery Sciences International (NASDAQ:BDSI) i... | medcitynew... |
| - | BDSI: Pharma partners still interested in pain drug’s $500M ... | Before BioDelivery Sciences International (NASDAQ:BDSI) released early phase 3 clinical trial result... | medcitynew... |
| - | BDSI’s cancer pain product preps for Europe, triggers $2.5M ... | The breakthrough cancer pain treatment developed by BioDelivery Sciences (NASDAQ:BDSI) International... | medcitynew... |
| - | Patent award to BDSI triggers $15M milestone payment from En... | A drug delivery technology patent awarded to BioDelivery Sciences International (NASDAQ:BDSI) has tr... | medcitynew... |
| - | FDA concerns delay relaunch of BDSI cancer pain product Onso... | Plans to relaunch breakthrough cancer pain treatment Onsolis are now delayed indefinitely until BioD... | medcitynew... |
| - | BDSI to get patent; issuance triggers $15M milestone from pa... | BioDelivery Sciences International (NASDAQ:BDSI) stands to gain a $15 million milestone payment afte... | medcitynew... |
| - | FDA’s REMS program puts BDSI at a disadvantage in cancer dru... | Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tou... | medcitynew... |
| - | BDSI pain drug fails in phase 3 trials but company plans new... | A pain drug candidate from BioDelivery Sciences International (NASDAQ:BDSI) failed to perform better... | medcitynew... |
